Conference Proceedings
The role of CYP2D6 mediated tamoxifen metabolism in the suppression of ovarian function trial (SOFT)
Matthew P Goetz, Gini F Fleming, Mary Kuffel, John R Hawse, John L Black, Richard Weinshilboum, James N Ingle, Patrizia dell'Orto, Olivia Biasi, Roswitha Kammler, Sherene Loi, Marco Colleoni, Giuseppe Viale, Prudence A Francis, Meredith M Regan
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2021
Abstract
Abstract Tamoxifen (T) is a pro-drug that undergoes CYP2D6-mediated metabolic activation to metabolites that more potently inhibit estrogen stimulated growth compared to the parent drug. While many studies have examined the role of CYP2D6 genotype in T-treated postmenopausal women, the role of CYP2D6 metabolism in premenopausal women (pre-MW) receiving T, with or without ovarian function suppression (OFS) or exemestane (E) and OFS is unknown. Methods: SOFT randomized 3066 (pre-MW) from 2003-2011 in 27 countries, stratified according to prior receipt or nonreceipt of chemotherapy and nodal status, to receive 5 years of T, T+OFS, or E+OFS. We designed a pharmacogenetics substudy..
View full abstract